Navigation Links
Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
Date:4/9/2008

SAN CARLOS, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has ceased all negotiations with potential partners for its inhaled insulin programs as a result of new data analysis from ongoing clinical trials conducted by Pfizer Inc. An increase in the number of new cases of lung cancer was observed in inhaled insulin patients as compared to the control group. All new incidences of lung cancer were in patients that are former smokers.

"The concern over this new data analysis from ongoing clinical trials has resulted in the termination of all negotiations with potential partners," said Howard W. Robin, President and CEO of Nektar. "Fortunately, over the past year Nektar has significantly transformed its business, moving away from inhaled insulin. We have made great progress expanding our research efforts and have built a deep pipeline of novel partnered and proprietary drugs in various stages of development."

Nektar will cease all spending associated with its inhaled insulin programs and will not incur any additional charges related to this event.

The Exubera label was updated by Pfizer to contain the following safety information warning:

"In clinical trials of Exubera, there have been 6 newly diagnosed cases of primary lung malignancies among Exubera-treated patients, and 1 newly diagnosed case among comparator treated patients. There has also been 1 post-marketing report of a primary lung malignancy in an Exubera-treated patient. In controlled clinical trials of Exubera, the incidence of new primary lung cancer per 100 patient-years of study drug exposure was 0.13 (5 cases over 3900 patient-years) for Exubera-treated patients and 0.02 (1 case over 4100 p
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
2. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
3. OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection
4. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
5. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
6. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
7. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
8. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
9. Potential Early Warning System for Lung Cancer Identified
10. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
11. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... the District of New Jersey ... against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... that U.S. Patent No. 6,765,117 is both valid and ... its generic product until the expiration of that patent ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a ... and New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists ... advancements that hyperspectral imaging can bring to examination ... , Director of Product Development at ChemImage, will ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, ... (OTCQB: DMPI) ("DelMar" "the Company") today announced the filing ... Company recently changed its fiscal year end to June ... its common stock on a national securities exchange in ... as filed with the United States Securities Exchange Commission ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
(Date:8/29/2014)... (PRWEB) August 29, 2014 A team ... wellness solutions, is on its way to the 2014 ... San Diego Convention Center to exhibit and demonstrate a ... in high-noise industrial environments. Etymotic’s safety earphones and high-definition ... technology devices at the show. , The company’s ...
(Date:8/29/2014)... City, Calif. (PRWEB) August 29, 2014 ... and customer service solutions, today announced that LiveOps has ... Muscular Dystrophy Association's (MDA) Show of Strength Telethon for ... entertainment event raises money and awareness to support MDA’s ... dystrophy, an aggressive and sometimes fatal muscle disease. This ...
(Date:8/29/2014)... 29, 2014 (HealthDay News) -- Prostate cancer patients lacking ... decisions. This can lead to worse quality of care ... included 70 men, with a median age of 63. ... Poor understanding of the disease was associated with greater ... that the treatment would be effective, the study found. ...
(Date:8/29/2014)... Medicine have identified one way the Ebola virus dodges ... lead to new therapies, in research results ... . , In work performed at Beamline 19ID at ... a detailed map of how a non-pathogenic Ebola protein, ... molecules in and out of the cell nucleus. , ...
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... inventor from Harrisburg, Pa., had to have breast reconstruction. ... to be sub-par, so she decided that there needed ... a better look for a woman or man who ... visible, as well as promotes confidence and peace of ...
Breaking Medicine News(10 mins):Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 3Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 4Health News:Faced With Prostate Cancer, It Helps to Know the Enemy 2
... function a serious concern, researchers say , TUESDAY, Jan. 26 (HealthDay ... with the virus that causes AIDS, new research suggests. , It,s ... -- or both -- are contributing to the aging. But one ... the same as in those of uninfected people who are 15 ...
... Clinicians use Epocrates ... ... -- Epocrates, Inc., a leading developer of mobile clinical and decision support software, ... 2009. The market demand and clinician need for its mobile and online solutions among large ...
... progression, study finds , TUESDAY, Jan. 26 (HealthDay ... drug pazopanib (Votrient) slowed their disease progression by 54 ... 3 study included 233 patients with previously untreated kidney ... locally advanced or had spread, and 202 patients with ...
... ... to push fans to reach their fitness goals with the 5-Hour Energy Workout Challenge. , ... Farmington Hills, MI (PRWEB) January 26, 2010 -- ... fitness goals with the 5-Hour Energy Workout Challenge ., , , , ,The Workout Challenge ...
... , SYRACUSE, N.Y. , Jan. 26 ... recent earthquake in Haiti , Aspen Dental Management, Inc. (ADMI) ... ," a voluntary program that gives Aspen Dental employees the option ... Red Cross for Haiti relief and development. Aspen Dental ...
... As the debates about "eat this -- not that" ... the record straight about what sweetens most of the non-diet beverages ... Syrup 55 (HFCS), not sugar (sucrose).   , In hundreds of ... sugar is misidentified as a prominent soda sweetener. Terms like "sugary ...
Cached Medicine News:Health News:Premature Aging of the Brain Seen in HIV Patients 2Health News:Health Systems, Hospitals and Universities Nationwide Chose Epocrates in 2009 for Trusted Point-of-Care Clinical Information 2Health News:Health Systems, Hospitals and Universities Nationwide Chose Epocrates in 2009 for Trusted Point-of-Care Clinical Information 3Health News:New Drug Slows Advanced Kidney Cancer 2Health News:The 5-Hour Energy Workout Challenge 2Health News:The 5-Hour Energy Workout Challenge 3Health News:Aspen Dental Employees to Give 'An Hour for Haiti' 2Health News:Sugar Association Seeks to Set the Record Straight on 'Sugar-Sweetened Beverage' Terminology 2
IDS Rapid One, a microbial identification system....
IDS Rapid NF Plus, a microbial identification system....
Versatrek 240 is versatile as four tests can be performed on one platform such as blood culture, sterile body fluids, mycobacteria and mycobacteria susceptibility testing. This model comes equipped w...
BD Phoenix is an automated microbiology system used for identification and susceptibility testing....
Medicine Products: